Moderna is expected to announce its second-quarter results in the upcoming month, and analysts expect a slight reduction in ...

The multicomponent mRNA-1083 vaccine elicited noninferior immune responses in adult patients when compared with coadministered influenza and COVID-19 vaccines.

The average short interest for the S&P 500 Health Care Index Sector (NYSEARCA:XLV) experienced an increase in June, moving ...

What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 3.6% in the morning session after JPMorgan added ...

The mRNA technology behind the Pfizer and Moderna vaccines are groundbreaking, but their potential goes way beyond COVID-19.

In light of recent revelations surrounding a new intranasal COVID-19 vaccine candidate, there is growing concern that the American public is once again being led into potentially dangerous territory ...

Moderna’s COVID-19 vaccine has received full FDA approval for use in children at higher risk for severe illness.

This stock used to be a highflyer but has struggled in recent years as demand waned for its flagship product. Though Moderna ...